Make sense. Radiation hardens the pancreas. Sutures hold better. 👇🏼👇🏼

Preop chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy ⁦SURGERY Journal⁩ ⁦Marc Besselink⁩ surgjournal.com/article/S0039-…

🚨Pelvic lymph node XRT improves survival for young men w/ #prostatecancer 🚨

Journal of Clinical Oncology ASCO

🗓️Median f/u 10.2 years, n=350

☢️For men <65 years WPRT improved
✅OS: HR 0.33
✅PCSM: HR 0.17

👉Post-hoc analysis of an RCT from 2005!!! Before any PSMA PET

Huge thanks to Albert Koong, MD PhD from MD Anderson Cancer Center for joining us as our Visiting Professor! Thank you for spending your birthday with us and for sharing your wisdom and invaluable insights! #radonc #meded

‼️🚨ASCO #ASCO24 abstracts LIVE now! Join us June 2 for our teams ORAL🙌👏 abstract on work led by Amin Nassar, MD that will presented by RitujithJayakrishnan on consolidation ALK in locally advanced NSCLC. Elio Adib JessicaJLinMD Jair Bar Ana I. Velázquez Mañana, MD MSc (she/her/ella) and others !

Stepping onto the idyllic American University of Beirut campus brings back a flood of memories. Grateful for the friendships, mentorship, and experiences that paved the way for my journey!

Warm welcome to our new #BMCCancer Editorial Board Members Elio Adib, Antonio Di Meglio, MD, PhD and Gregory Chesnut. We look forward to working with you! Interested in joining #BMCCancer ? Visit <bmccancer.biomedcentral.com/join-our-edito…>.

Looking forward to talking about ancestry-specific biases in tumor mutational burden with Alanna Church, MD in a few weeks! Related to our prior work here: pubmed.ncbi.nlm.nih.gov/36179682/

SENOMAC:

cT1-T3 breast cancer w/ 1-2 SLN macrometastases -> SLN only vs completion ALND

RT in 90%

HR for recurrence or death of 0.89 (95% CI, 0.66 to 1.19) - favoring SLN only!

More data for AxRT #radonc and omission of ALND!

nejm.org/doi/full/10.10…

🚨🚨‼️Thrilled to be invited to deliver the PLENARY Translational talk SWOG Cancer Research Network SWOG Cancer Research NetworkChair as part of the 2022 #HOPE -foundation Impact Award The Hope Foundation for Cancer Research @Seattle April 4, 3.30 pm. Elad Sharon OU Health Stephenson Cancer Center. Will highlight our multiomics work on Alveolar soft part sarcoma!

METIS positive randomized trial!
Met Primary Endpoint
Tumor Treatment fields significantly delay time to intracranial progression
novocure.com/metis-phase-3-…

Thanks Brigham and Women's Hospital On-A-Mission for highlighting our work published in JTO & JTO CRR!

Important data for patients with unresectable, stage 3, EGFR-driven NSCLC as we eagerly await the LAURA trial results.

#lcsm

brighamhealthonamission.org/2024/03/26/pat…

Amin Nassar, MD Rafeh Naqash, MD

Can't find a better fit for ARRO education exec!⭐
As a PGY-2 at Harvard Radiation Oncology Residency Program, Shane is already leading the way by sharing valuable educ resources with us. He's also always ready to 'hop on FaceTime' for support for all matters #radonc education. Go Shane!📩

Hey Rad Onc Residents!

🗳️ Voting is open for ARRO Executive Committee! There are many great candidates and it is no easy choice.

Would love for you to consider supporting my bid for the Education Committee! 🤓

You should get an email with instructions for how to vote.

New #JITC article: Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes bit.ly/49Kdnfp Amin Nassar, MD Talal El Zarif, MD Rafeh Naqash, MD Elad Sharon Alessio Cortellini Shruti Gupta Toni Choueiri, MD Guru P. Sonpavde, MD

Variability in GTV delineation remains the biggest challenge in radiotherapy planning. In this paper, we propose a solution using pre-existing FDG-PET images for the GTV delineation of soft tissue sarcoma. ⁦Radiotherapy & Oncology⁩⁦ ⁦ASTRO⁩⁦ scholar.google.com/citations?view…

1/ For #KidneyCancerAwareness month The Lancet Oncology has a 50-day full link to TROG Cancer Research FASTRACK II! authors.elsevier.com/a/1ifvZ5EIIgPd…. Thank you Cancer Australia, ANZUP, Varian. A new #radiotherapy standard of care option for inoperable primary #kidneycancer #radonc

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing. Amin Nassar, MD Yale Cancer Center Elias Bou Farhat Dana-Farber Brigham and Women's Hospital #oncology #crc onclive.com/view/complemen…

In a multi-institutional study published in JTO & JTO CRR, Elio Adib & @danafarber researchers show that in Stage 3 unresectable #lungcancer , treatment with consolidation osimertinib has superior PFS compared to consolidation durvalumab or observation.
🔗 ms.spr.ly/6011ivYFF

Should consolidation Osimertinib be considered in EGFR-mut stage III NSCLC post-CRT?
✅Improved PFS (vs. durva & obs)
✅Less gr3+ AE
⁉️OS⁉️ (awaiting LAURA)

Led by: Amin Nassar, MD Rafeh Naqash, MD
So Yeon Kim #SarahGoldberg

Ray Mak, MD Harvard Radiation Oncology Residency Program #lcsm

jto.org/article/S1556-…